Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.



San Francisco, CA, USA

Prellis Biologics

Synthetic biology

3D printing

Cantos Ventures is a pre-seed and seed-stage venture capital fund that invests in startups in 'pre-inflection' industries. We view every startup as a journey, and seek to join those with noble aims.

Your story awaits